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Abstract
Aims Transplantation of bone marrow-derived haemopoietic stem cells following streptozotocin (STZ) treatment
to induce pancreatic beta cell loss in mice causes the partial
regeneration of beta cell mass, with many haemopoietic
cells demonstrating endothelial cell markers. This study
used genetically tagged haemopoietic lineage-derived cells
to determine how endogenous cells are mobilised following
beta cell loss and subsequent replacement.
Methods A double transgenic mouse model, Vav-iCre;
R26R-enhanced yellow fluorescent protein (YFP), was used
where only haemopoietic lineage cells expressed the Vav1
gene promoter allowing expression of the YFP reporter
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gene. Between postnatal days 2 and 4 mice were injected
with STZ or vehicle (control) and body weight and
glycaemia were monitored. Mice were killed between
days 10 and 130, and the pancreases were examined by
immunofluorescence microscopy.
Results YFP-expressing cells infiltrated the pancreas at all
ages, being present around newly forming islets at the
pancreatic ducts, and within larger islets. Small numbers of
YFP-positive cells (<5%) co-stained for the macrophage
markers F4/80 or Mac1, for cytokeratin 19, or for the
transcription factor pancreatic and duodenal homeobox 1
(PDX-1), but no co-localisation was seen with insulin or
other endocrine hormones. Within islets approximately
30% of YFP-positive cells co-stained for the endothelial
cell marker CD31, and following STZ the number of
haemopoietic-derived cells, and the proportion that were
CD31-positive, both significantly increased after 21 and
40 days, coincident with a partial replacement of beta cells.
Conclusions Our results suggest that following beta cell
loss endogenous haemopoietic-lineage cells contribute to
intra-islet angiogenesis, which supports a partial recovery
of beta cell mass.
Keywords Endothelial cell . Haemopoietic . Regeneration .
Vav
Abbreviations
GTT
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Introduction
Transplantation of bone marrow cells, or separated fractions
of marrow progenitor cells have been shown to facilitate the
reversal of diabetes in experimental animals, and newly
diagnosed individuals with type 1 diabetes [1–4]. In some
studies a direct trans-differentiation of bone marrow stem
cells into insulin-positive beta cells has been demonstrated,
either in vivo or following lineage manipulation in vitro [5–
7], but the direct contribution of haemopoietic stem cells to
a new beta cell population has generally been found to be
low and inconsistent with the associated increase in insulin
secretion and normalisation of blood glucose [1, 8–10].
One mechanism for beta cell regeneration would appear
to result from the differentiation of marrow-derived
vascular progenitors into endothelial precursor cells, present either as isolated cells that can infiltrate the islets and
pancreatic ducts, or as cells that become incorporated as
differentiated endothelial cells into the pancreatic microvasculature during angiogenesis [1, 11]. Angiogenesis was
accompanied by an increase in endogenous beta cells by
replication, or by neogenesis of new islets from the
pancreatic ducts [1, 8]. Pancreatic vascular endothelium
can induce beta cell differentiation, while also providing
key signals via a shared basement membrane for beta cell
growth and function [12, 13]. A paracrine interplay within
the islet allows a synthesis of vascular endothelial growth
factor from the beta cells to contribute to endothelial cell
proliferation, whereas a reciprocal production of hepatocyte
growth factor by the endothelial cells promotes beta cell
growth [14].
Most studies on the contribution of marrow-derived stem
cells to beta cell survival or regeneration have used
transplantation of cells, sometimes with a genetic tag such
as green fluorescent protein, into irradiated recipient
animals made diabetic through beta cell ablation with
streptozotocin (STZ) or the use of diabetes-prone animals
such as the NOD mouse strain [15, 16]. As little as 1%
allogeneic chimerism of repopulated marrow was able to
reverse disease in the NOD mouse diabetes model [16].
However, in a pathological series of human pancreases
from individuals who had previously received haemopoietic
stem cell transplants from opposite sex donors, there was
no evidence of colonisation of these cells within the islets
[17]. The mobilisation of marrow stem cells to colonise the
pancreas appears to be linked to the presence of pancreatic
tissue damage, in either the endocrine or exocrine compartments [18, 19].
Wang et al. [20] showed that when adult, green
fluorescent protein-tagged bone marrow cells were transplanted into neonatal mice a proportion of these cells transdifferentiated into pancreatic ductal epithelium, a source of
islet neogenesis in early life. However, there is little
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evidence about the contribution of endogenous marrow
stem cells to normal pancreatic endocrine development, or
beta cell regeneration during early life. We therefore used
animals producing an improved Cre recombinase under the
control of Vav1 promoter elements, which were crossed
with transgenic mice expressing LoxP (also known as Lox)
yellow fluorescent protein (YFP) to generate mice in which
haemopoietic lineage cells could be tracked anatomically.
The guanine nucleotide exchange factors of the Vav family
catalyse the exchange of GDP for GTP and activate the Rho
family of GTPases, which are linked to growth factorinduced tyrosine kinase receptor activation [21]. Rho
GTPases are associated with the control of the cytoskeleton,
cell migration and differentiation, including the morphogenesis of capillaries [22]. The Vav1 gene is ubiquitously
expressed by all haemopoietic lineage cells, and their
differentiated cell progeny including T cells, B cells and
macrophages [23, 24]. It is also expressed in progenitor
cells of the testis, but not in other non-haemopoietic tissues.
The related Vav2 and Vav3 genes are more widely
expressed, particularly in vascular tissue [25]. We have
used Vav1-Cre/YFP mice to explore haemopoietic lineage
cell migration to the endocrine pancreas during early
postnatal development, with or without beta cell damage,
and the resulting phenotype of these cells.

Methods
Animals Mice containing a yellow fluorescent protein gene
construct (B6.129X1-Gt(ROSA)26Sortm1(EYFP)Cos/J) (R26REYFP) were obtained from Jackson Laboratories, Bar
Harbor, ME, USA, and maintained as homozygotes. Vav1
promoter (HS21/45)-iCre animals generated by D. Kioussis, National Institute for Medical Research, London, UK
[23] were kindly provided by W. Hazenbos, Osaka
University, Japan and maintained as heterozygotes by
backcrossing with C57BL/6 mice. The animals were
housed in temperature-controlled rooms with a 12 h light–
dark cycle and were given food and water ad libitum.
Experimental animals were obtained by crossing R26REYFP with the Vav-iCre strain. Double transgenic offspring
(Vav-iCre;R26R-EYFP) were then identified by polymerase
chain reaction of genomic DNA following an ear biopsy
using the following primers: iCre sequence 5′-AGA TGC
CAG GAC ATC AGG AAC CTG; 5′-ATC AGC CAC
ACC AGA CAC AGA GAT C and R26R-EYFP sequences
oIMR0316 5′-GGA GCG GGA GAA ATG GAT ATG;
oIMR0883 5′-AAA GTC GCT CTG AGT TGT TAT;
oIMR4982 5′-AAG ACC GCG AAG AGT TTG TC.
Litters were randomly chosen to receive either a subcutaneous injection of 35 mg/kg STZ (Sigma-Aldrich, Oakville,
ON, Canada) freshly prepared in citrate buffer (pH 4.5), or
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a sham injection consisting of citrate buffer (pH 4.5) at 2
and 4 days of age. All pups from individual litters received
the same treatment regardless of genotype. Animals were
regularly weighed and their blood glucose levels were
measured using a glucometer (Ascencia Breeze2; Bayer
Inc., Toronto, ON, Canada) after 3–5 h of fasting by lancing
the tail vein to obtain 1 μl blood. Female and male VaviCre;R26R-EYFP animals from at least three different litters
for each group were killed at days 10, 21, 40, 60, 80 and
130, the last two representing adulthood, by CO2 asphyxiation. Pancreases, spleens and livers were collected
immediately after dissection and fixed for histology.
Animal procedures were performed with the approval of
the Animal Ethics Committee of the University of Western
Ontario, and in accordance with the guidelines of the
Canadian Council on Animal Care.
Tissue preparation Tissues were fixed in 4% paraformaldehyde/PBS overnight at 4°C. Tissues were then washed three
times for 10 min each in PBS, sequentially incubated in 5%,
10% and 15% sucrose for 1 h each and embedded in OCT
(Tissue-Tek, VWR International, Mississauga, ON, Canada)
over dry ice. Cryosections 7 μm thick were placed on
SuperFrost Plus glass slides (Fisher Scientific, Toronto, ON,
Canada), and stored at −80°C with desiccant in an airtight bag.
Immunofluorescence Sections of pancreas were used for
immunofluorescence analysis using the following primary
antibodies: guinea pig anti-insulin (1:500; Abcam Inc.,
Cambridge, MA, USA), mouse anti-insulin (1:10,000;
Sigma Chemical Co., St Louis, MO, USA), rabbit antiGFP (1:200; Abcam) for YFP detection, mouse anti CD31
(1:50; Hycult Biotechnology, Uden, the Netherlands),
guinea pig anti-pancreatic and duodenal homeobox 1
(PDX-1) (1:1,000; kindly provided by C. Wright, University of Vanderbilt), rat anti-F4/80 (1:10; Abcam), rat antiCD11b (Mac1, 1:20; BD Biosciences, Mississauga, ON,
Canada), mouse anti-vimentin (1:100; Santa Cruz Biotechnology, Santa Cruz, CA, USA), mouse anti-glucagon
(1:2,000; Sigma), mouse anti-somatostatin (1:100; Santa
Cruz), mouse anti-pancreatic polypeptide (1:100; Santa
Cruz), goat anti-human glucose transporter 2 (GLUT2,
1:50; Santa Cruz), rabbit anti-v-maf musculoaponeurotic
fibrosarcoma oncogene family, protein A (avian) (MAFA)
(1:1,000; Abcam), rabbit anti-surfactant protein D (1:100; a
kind gift from J.R. Wright, West Virginia University), and
rabbit anti-Ki67 (1:200; ThermoScientific, Freemont, CA,
USA). DAPI (1:3,000) was used for visualisation of nuclear
DNA. Secondary antibodies used were goat AlexaFluor
488 and 555 purchased from Invitrogen Canada Inc.,
Burlington, ON, Canada and used at dilutions of 1:200 to
1:500. Co-staining of the sections with YFP and each of the
other markers was performed to determine co-expression
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for each cell type. Liver and spleen sections were stained
for YFP and macrophage markers cell surface glycoprotein
MAC-1 alpha subunit (MAC1) and cell surface glycoprotein F4/80 (F4-80).
Morphometric analysis Pancreas tissue sections from at
least three independent litters for each sex were examined
at 10, 21, 40 and 130 days old. Images were processed
using Image J software (US National Institutes of Health,
Bethesda, MD, USA, http://rsb.info.nih.gov/ij/, 1997–
2009). The number of YFP-positive cells within an islet
was counted and calculated relative to the total number of
cells, or to the number of beta cells in the islet. Islet and
total beta cell area were measured, and the percentage of
beta cells per pancreatic section was calculated to estimate
the beta cell mass in the entire pancreas. The co-localisation
of YFP to endothelial cells was achieved using the
endothelial marker CD31. Twenty fields of view were
randomly chosen per animal (containing pancreatic parenchyma and islets) and the number of cells positive for both
markers relative to the total number of YFP-positive cells
was calculated. Similar methodology was used to colocalise other phenotypic markers to YFP cells, using a
population of 1,500 to 2,000 cells per pancreas.
Statistical analysis Results were expressed as mean values ±
SEM. Differences between groups were examined for
statistical significance using two-way ANOVA, followed by
Student Newman–Keuls post hoc test when interaction was
present. Values of p<0.05 were considered statistically
significant. Values for all measurements were found to be
similar for male and female mice, and the data were
therefore subsequently combined.

Results
Double transgenic Vav-iCre/R26R-EYFP mice were of
normal birthweight (1.57±0.04 g) and showed comparable
growth rates for each sex until 130 days, the maximum age
followed, to the single transgenic strains. Animals treated
with STZ showed a small but significant decrease in body
weight gain with age compared with controls (Table 1).
Following STZ treatment hyperglycaemia was transient and
was not different from control animals at day 10. However,
relative hyperglycaemia was again seen after 14 days,
which persisted until 130 days and was greater in male
mice than in female mice (Table 1). Glucose tolerance in
control Vav-iCre animals assessed by a glucose tolerance
test (GTT) was normal at 80 and 130 days (Fig. 1) of age.
STZ-treated mice had fasting hyperglycaemia and were not
subjected to a GTT.
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Table 1 Body weight and
fasted serum glucose concentrations for male or female Vav-Cre
transgenic mice from 10 to
130 days of age, with or without
treatment with STZ
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Age (days)

10
14
21
40
60
80

Values represent mean ± SEM;
n=10–43 animals representing
three to five separate litters

130

*p≤0.05 vs control

Treatment

Female mice

Control
STZ
Control
STZ
Control
STZ
Control
STZ
Control
STZ
Control
STZ

6.8±0.2
7.5±0.5
6.6±0.2
8.2±0.5*
6.7±0.1
8.5±0.3*
8.2±0.4
19.6±1.4*
7.6±0.3
26.6±1.4*
8.6±0.2
23.7±2.1*

Control
STZ

8.7±0.3
19.2±3.0*

Blood glucose (mmol/l)

35
30
25
20
15
10
5
0

30

60

90

Body weight (g)

Male mice

When the spleen of Vav/YFP animals was examined at
day 21 splenocytes were seen to uniformly express YFP
fluorescence (Fig. 2a), and a subpopulation also expressed
the macrophage markers F4/80 and Mac1, demonstrating
the retention of the genetic marker within differentiated
progeny (Fig. 2b). The YFP-positive cells were also seen
throughout the liver as endothelial cells lining the sinusoids, and within the Kupffer cells as localised using F4/80
(Fig. 2c). Haemopoietic lineage YFP-positive cells were
found within the pancreas of Vav/YFP mice at all ages
studied up to adulthood, but showed a significant decrease
in abundance with age (Table 2). YFP-expressing cells were
located within the parenchyma, lining the pancreatic ductal
epithelium, and around and within the islets of Langerhans
(Fig. 3a, b). Haemopoietic lineage cells surrounding the
ducts were small and elongated, as were those around the
periphery of the islets. Of the duct-associated YFPexpressing cells, 8.6±1.2% co-stained for cytokeratin 19
on day 40, indicating a probable trans-differentiation into a
ductal phenotype (Fig. 3b–e). A similar percentage of cells
co-localised YFP and cytokeratin 19 on day 21, but few

0

Glucose (mmol/l)

120

Time (min)

Fig. 1 Glucose values (mmol/l) during a GTT at 130 days in male
(black line) or female (grey line) Vac-Cre mice. Figures represent
mean values ± SEM for six animals derived from three separate litters

Male mice

Female mice

6.9±0.5
6.8±0.3
6.9±0.5
8.1±0.4*
6.9±0.2
8.7±0.3*
6.3±0.4
11.0±0.5*
7.4±0.4
13.7±1.5*
8.1±0.2
14.7±1.2*

5.64±0.14
5.55±0.16
7.64±0.23
7.07±0.15
10.09±0.34
8.84±0.18*
21.60±0.29
19.35±0.41*
26.01±0.51
22.40±0.57*
29.61±0.47
25.86±0.59*

5.54±0.19
5.51±0.21
7.52±0.33
7.17±0.15
10.16±0.35
8.71±0.21*
17.50±0.23
16.36±0.29*
19.86±0.33
18.00±0.55*
22.95±0.29
21.04±0.31*

7.5±0.2
13.1±2.7*

39.14±0.76
31.80±1.48*

26.81±0.56
24.17±0.57*

such cells were seen at day 130. When small islets were
seen adjacent to the ductal epithelium, probably representing neogenesis of new endocrine tissue, the haemopoietic
cells were found to completely line the small islets and the
adjacent ductal epithelium (Fig. 3a).
In contrast to the YFP-labelled cells associated with
ducts, lineage-marked cells within the central core of the
islets were large and irregularly shaped. Haemopoietic
lineage cells accounted for approximately 6–8% of the islet
cell population in control transgenic animals, and this did
not significantly change with age (Fig. 4a). Based on
calculation of the number of beta cells in the same islets
this represented around a 1:8 frequency ratio of haemopoietic cells to insulin-immunoreactive beta cells. YFPexpressing cells were distributed throughout the acinar
tissue with a frequency of 3.5% relative to the total number
of acinar cells determined from nuclear staining with DAPI.
Co-staining of Ki67 in YFP-expressing cells in either islets
or acinar was rare, with only l.3±0.2% of such cells
showing Ki67 immunoreactivity within the islets.
Following treatment of mice with STZ there was no
change in the number of haemopoietic lineage cells seen
within the pancreas at day 10, but the numbers of cells
found in the whole pancreas, and specifically within the
islets, significantly increased at days 21 and 40, and
returned to control values by adulthood at day 130
(Fig. 4a, Table 2). At day 21 the ratio of haemopoietic
cells to insulin-immunoreactive beta cells within the same
islets increased to approximately 1:3. This might be
accounted for partly by the initial loss of beta cells
following STZ. However, analysis of the beta cell area
per islet in STZ-treated mice (Fig. 4b) showed that this had
recovered to control values by day 21. The recovery of beta
cell area after STZ treatment could not be maintained into
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Fig. 2 Immunofluorescent localisation of YFP (green) in splenocytes
from Vav/YFP transgenic mice aged 21 days (a). YFP-expressing
macrophage precursors were co-localised within spleen by F4-80
immunofluorescence (b, red). Within liver YFP was localised to
sinusoidal epithelial cells and also co-localised with F4/80 within
Kupffer cells (c, red, arrows). Nuclei are shown by DAPI stain in blue.
Scale bar, 250 μm

adulthood and was significantly lower than in control mice
by day 130. When total beta cell mass was calculated,
including all extra-islet insulin-immunoreactive cells, it was
found to be decreased after STZ by around 80% at day 10
(Fig. 4c). By day 21 beta cell mass had recovered to 50–
60% of control values, but regeneration was not sustained,
Table 2 The number of YFP-positive haemopoietic lineage cells
present per square micrometre of pancreas in Vav-Cre transgenic mice
between 10 to 130 days of age, with or without treatment with STZ
YFP-positive cells/μm2 ×10−3

Age (days)

Treatment

10

Control

2.3±0.1

STZ
Control
STZ
Control
STZ
Control
STZ

2.2±0.1
1.6±0.1*
4.9±0.1**
1.2±0.1*
2.4±0.1**
1.3±0.1*
1.1±0.1

21
40
130

Fig. 3 a Immunofluorescent localisation of insulin (red) and YFP
(green) around a pancreatic duct (D) within a Vav/YFP transgenic
mouse aged 21 days. A small islet (arrow) adjacent to the ductal
epithelium is shown lined by YFP-positive haemopoietic cells. b YFPpositive haemopoietic cells (green, arrow) were localised within the
core of the islets (I) in mouse pancreases. The section was co-stained
for cytokeratin 19 (red) to identify ductal epithelial cells. Some YFPpositive cells co-stained with cytokeratin 19 as shown within the inset
in (b). This is shown at higher magnification in (c) cytokeratin, (d)
YFP and (e) combined and with nuclei shown as blue by DAPI stain.
Scale bars: 200 μm in a and b; 35 μm in c–e

Data from male and female animals were combined. Values represent
mean ± SEM; n=10 to n=12 animals representing three separate
litters
**p≤0.01 vs control for same age, *p≤0.05 vs control day 10

being 33% of control values at day 40 and only 10% of
control values at day 130. The timing of a partial recovery
of beta cell mass following STZ therefore coincided with an
increased number of haemopoietic cells around and within
the islets.
We examined the phenotypic identity of the haemopoietic
lineage cells within the pancreas, and found no co-localisation
of immunoreactive insulin or glucagon (Fig. 5a, b), somatostatin or pancreatic polypeptide (not shown). However,
approximately 30% of YFP-positive cells showed costaining with the endothelial cell marker, CD31 (Fig. 5c–g).
Such cells were found within and surrounding the islets, as
well as within the parenchyma, and were typically small and
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c

Beta cell area/islet (µm2)

Beta cell mass (mg)

b

% YFT+ cells/islet

a

10

21

40

Age (days)

130

10

21

40

Age (days)

130

10

21

40

130

Age (days)

Fig. 4 a Percentage of YFP immunofluorescent cells within pancreatic islets of Vav/YFP transgenic mice following treatment with STZ
(closed bars) or control (open bars) between 10 and 130 days of age.
b The area of islets occupied by insulin-immunoreactive cells. c The
pancreatic beta cell mass within the same animals. Figures represent

mean values ± SEM for six animals derived from three separate litters.
*p≤0.05 for comparisons between STZ and control-treated animals at
each age. ap<0.05 vs all other ages within treatment, bp<0.05 vs day
10, cp<0.05 vs day 21, dp<0.05 vs day 130

elongated. The percentage of CD31-positive/YFP-positive
cells within the pancreas was significantly increased 21 days
(control 25±3%, STZ 37±3%, p<0.05) and 40 days (Fig. 6)
after administration of STZ, but had returned to control
values by day 130 (20±2%). The macrophage markers F4/80
and Mac-1 were also localised in pancreas, detected by
immunofluorescence. Approximately 5% of YFP-positive

cells present in the parenchyma and around the pancreatic
ducts and islets expressed these macrophage markers
(Fig. 7a, b), and this percentage did not change after STZ
treatment, or with age.
Large, YFP-positive cells within the islets did not costain with CD31, F4/80 or Mac1, but 2% of these cells
showed a co-localisation of PDX-1, suggesting that they
may represent endocrine cell progenitors (Fig. 7c–f). This
possibility is further supported by the co-localisation of
both GLUT 2 and surfactant protein D within intra-islet
YFP-positive cells (Fig. 8), although they did not express
the transcription factor MAFA, which is a marker of beta
cell differentiation, or any of the pancreatic endocrine

Fig. 5 Lack of immunofluorescent localisation of insulin (red) and
YFP (green) (a), or glucagon (red) and YFP (green) (b) within the
islets of Vav/YFP transgenic mouse aged 40 days. Two islets (c,d) are
shown with YFP (green) co-stained for CD31 (red). Some YFPexpressing cells located particularly around the periphery of the islets
co-expressed CD31 (indicated ‘3’ and examples located by arrows).
One CD31-positive cell is outlined within the inset in (d) and shown
at higher magnification stained for YFP alone (e), CD31 alone (f), or
combined with DAPI stain to indicate nuclei (g, blue). Scale bars:
200 μm for a–d, 30 μm in e–g

Fig. 6 Cells dual-labelled for YFP and CD31 within pancreatic islets
and parenchyma were counted and expressed as a percentage of the
total number of YFP-positive cells per islet in control (white bar;
1,700 YFP-positive cells) and STZ-treated (black bar; 1,800 YFPpositive cells) animals aged 40 days. Figure represents mean values ±
SEM for six animals derived from three separate litters. *p<0.001 vs
control
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Fig. 8 Immunofluorescent localisation of GLUT2 alone (a, red) and
co-localisation with YFP (b, green), and of surfactant protein D alone
(c, red) and co-localisation with YFP (d, green) within pancreatic
islets of a Vav/YFP transgenic mouse aged 40 days. GLUT2
localisation is apparent on the plasma membranes of both beta cells
within the core of the islets and of YFP-positive cells (arrows). Scale
bar, 200 μm

Fig. 7 Immunofluorescent co-localisation (arrows) of the macrophage
marker F4/80 (a, red) and YFP (b, green) in the same pancreatic tissue
section within a Vav/YFP transgenic mouse aged 40 days. Nuclei are
shown with DAPI stain (blue). A pancreatic islet is shown in (c) costained for YFP (green) and PDX-1 (red). Islet cells demonstrated a
nuclear presence of PDX-1 with some cells also being YFP-positive.
An example of a co-stained cell is shown within the inset, and at
higher magnification in (d) PDX-1, (e) YFP and (f) combined. Scale
bars: 200 μm in a and b, 100 μm in c, and 30 μm in d–f

hormones. The frequency of haemopoietic lineage cells that
co-expressed PDX-1 did not change following STZ treatment,
but did decrease with age, no such cells being apparent at
130 days. No co-localisation was found of the mesenchymal
marker vimentin in the large intra-islet YFP-expressing cells,
and the frequency of co-staining of such cells with cytokeratin
19 was low at all ages (day 40, 1.2±0.8%).

Discussion
The interpretation of the results is dependent on the
specificity of expression of the YFP reporter gene to
haemopoietic lineage derived cells under the control of
Vav1 gene promoter elements. The expression construct
used was developed by Ogilvy et al. [26] and de Boer et al.
[23] and includes four haemopoietic-specific sites (HS21/

45) around exon 1 of Vav1 as well as a testis-specific
promoter near exon 2. Despite the presence of the latter,
expression of the reporter gene was not seen in testis and
was solely restricted to haemopoietic-derived cells, including thymocytes, splenocytes, T and B cells and endothelial
cells [23, 26]. In our studies, reporter YFP gene expression
was activated by Vav-Cre in the majority of splenocytes and
in the thymus. Vav1 was shown to be expressed highly in
cancers, including those in lung, breast and pancreatic
ductal adenocarcinoma [27], but there is no evidence of
expression in these tissues outside neoplasia.
As expected, haemopoietic-derived cells were present
within the pancreas at all ages between 10 and 130 days,
being most abundant in the neonate. No changes in
abundance were seen around weaning, when an alteration
in circulating immune cells might be expected to accompany transition to a solid, carbohydrate-rich diet. The
haemopoietic-derived cells included the expected lineage
progeny such as endothelial cells and monocytes/macrophages. However, the localisation and morphology of
haemopoietic lineage cells within the pancreas were not
random and were compatible with a functional interaction
with endocrine cells or their progenitors. Within the
pancreatic ducts of younger animals YFP-positive cells
were shown to cluster around small islets in close proximity
to the ductal epithelium. This is likely to represent
continuing neogenesis of islets from ductal progenitors
[28]. YFP-expressing cells occasionally co-stained for
cytokeratin 19, indicating a probable trans-differentiation
to a ductal epithelial phenotype, but none of these small,
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duct-associated YFP-expressing cells co-localised PDX-1.
Wang et al. [20] showed that when adult, green fluorescent
protein-tagged bone marrow cells were transplanted into
neonatal mice a proportion of these trans-differentiated into
pancreatic ductal epithelium. From our studies it seems
unlikely that haemopoietic-derived cells directly contribute
to an endocrine cell progenitor pool, at least with regard to
islet neogenesis. Similarly, the majority of YFP-expressing
cells associated with sites of islet neogenesis did not costain for the endothelial cell marker CD31. It is recognised
that endothelial cells and their precursors can contribute to
pancreatic beta cell replication and insulin release [1, 8],
but our findings suggest that other haemopoietic-derived
progenitors of progeny cells are also closely associated with
developmental islet neogenesis in the growing mouse.
Although it was to be expected that some haemopoietic
lineage cells would exhibit a phenotypic marker, CD31, of
endothelial cells or their precursors, these accounted for
almost 30% of haemopoietic cells within the pancreas and
did not significantly change with age. Such cells were
predominantly distributed within the microvasculature in
and around larger islets. Approximately 5% of pancreatic
haemopoietic lineage cells expressed macrophage lineage
markers, although only a proportion of macrophages
resident in adult mouse pancreas were shown to express
F4/80 [29]. A contribution of macrophages to normal islet
development has been demonstrated and reviewed by
Homo-Delarche and Drexhage [30]. Macrophages expressing F4/80 first appear in the developing mouse pancreas on
day e14.5 [29], and the culture of pancreatic rudiments with
macrophage colony-stimulating factor increased the number
of insulin-immunoreactive cells, suggesting that an increase
in macrophage number potentiated beta cell replication. In
the macrophage colony-stimulating factor 1-deficient gene
knockout mouse (op/op), animals develop osteopetrosis as
adults, but young animals suffer from abnormal islet
morphogenesis, a much reduced beta cell mass and
deficiencies in beta cell replication [31]. Islet neogenesis
at the pancreatic ducts was enhanced, suggesting that islets
can be formed, but that the beta cell population cannot
expand appropriately. There is also evidence that macrophages have a key role in islet angiogenesis through the
expression of matrix metallopeptidase 9 [19].
Many haemopoietic-lineage cells were apparent as large
cells within the body of established islets. These did not costain with any pancreatic endocrine hormone, or any of the
other phenotypic markers used. However, a minority of
such cells did co-localise the transcription factor PDX-1, a
marker of pancreatic progenitors entering endocrine, exocrine and ductal lineages, and of differentiated beta cells
[32]. The lack of co-staining with any endocrine hormone
makes it unlikely that such cells have the capability to
become functional endocrine cells, but they may represent
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early-stage progenitors that, nevertheless, have a trophic
effect on endocrine cell development. A resident population
of PDX-1-positive, but insulin-negative, cells has recently
been described in mouse islets but in that study conversion
to insulin-positive cells was possible [33]. Additional
markers of beta cell progenitor cells include MAFA, matrix
metalloproteinase 2, cytokeratin 19 and surfactant protein D
[34]. Large YFP-labelled cells within the core of the islets
did co-stain with GLUT2 and surfactant protein D, but not
with MAFA. This suggests that the cells do exhibit some
markers of a pancreatic endocrine lineage but are unable, at
least in this model, to functionally mature.
Evidence of any mechanistic contribution of haemopoietic lineage cells to the regulation of beta cell mass in
the pancreas was sought following its experimental depletion in the neonate using STZ. This reduced total beta cell
mass by more than 80%, and the area occupied by beta cells
within persisting islets by approximately 70%. Within the
islets the fractional area occupied by insulin-positive cells
had recovered fully by 21 and 40 days, but could not be
sustained in adulthood. Recovery was less complete when
expressed as total beta cell mass, including individual
insulin-positive cells and small clusters. Hyperglycaemia
occurred in mice 40 days after STZ treatment and lasting
into adulthood, this being greater in males than in females.
The long-term hyperglycaemia may have contributed to the
reduced beta cell mass seen at 130 days, although beta cell
mass did not differ with sex. We have recently reported the
ontogeny of beta cell replacement in the neonatal mouse
following STZ treatment using a similar regimen to this
study [35]. Beta cell mass was largely replaced within
30 days, predominantly from within existing islets.
The fractional number of haemopoietic lineage cells
located within islets following STZ was unchanged after
10 days, indicating no acute response to the extensive beta
cell destruction. However, numbers were significantly
increased at 21 and 40 days in parallel with beta cell
replacement within the islets. A similar pattern was found
when examining the number of haemopoietic lineage cells
per unit area of whole pancreas, suggesting that trafficking
was not only to the islets. The increased numbers of such
cells within the pancreas was not linked to persistent
hyperglycaemia because this was not apparent until 40 days
after STZ. When the percentage of islet-associated YFPpositive cells demonstrating an endothelial marker was
considered this was similarly increased, indicating that a
greater proportion of haemopoietic-derived cells contained
the endothelial cell marker during a period of beta cell
replacement. The findings are consistent with the increase
in beta cell number seen following the transplantation of
exogenous, marrow-derived haemopoietic cells into animals treated with STZ [1, 6]. The latter can be partially
explained by the differentiation of marrow-derived endo-
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thelial precursor cells into endothelial cells as part of an
angiogenic response within the pancreatic microvasculature [1, 11], accompanied by an increase in
endogenous beta cell replication [1]. Our results suggest
that endogenous haemopoietic lineage cells might play a
similar role. However, neither the increased pancreatic
presence of YFP-tagged cells, or the recovery of beta cell
mass was sustainable into adulthood in this model.
Pancreatic YFP-positive cells expressing macrophage
markers, cytokeratin 19 or PDX-1, did not show a change
in relative presence following STZ treatment, although the
relatively low frequency of such cells compared with those
demonstrating CD31 made quantitative sampling difficult.
In summary, using genetic tagging of haemopoietic
lineage cells we have shown their presence during normal
pancreatic development postnatally with at least four
progeny phenotypes, endothelial cells, macrophages, epithelial cells and PDX-1-expressing cells, showing differential distributions within islets and around ducts. Following
induced beta cell loss and subsequent recovery within
islets, the total number of islet-associated haemopoietic
lineage cells was increased and with a greater percentage
demonstrating an endothelial cell marker. The results are
consistent with a contribution of haemopoietic lineage
endothelial precursors to an angiogenic response within
the islet microvasculature following damage, which contributes to the recovery of beta cell mass.
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